Summit Therapeutics' ivonescimab shows strong efficacy in trials, with Cantor Fitzgerald predicting a 50% market share in the ...

We recently published a list of 13 Best Healthcare Dividend Stocks to Invest in. In this article, we are going to take a look ...

The addition of pembrolizumab to chemoradiotherapy improved survival outcomes for women with high-risk, locally advanced ...

Nothing drives down a drug’s price like competition. According the U.S. Food and Drug Administration (FDA), a drug’s ...

While the recent market dip has created bargains, some stocks have sufficiently lagged the market in the past year to warrant ...

AstraZeneca has tapped Korea's Alteogen to develop subcutaneous cancer drugs. Taiho Pharmaceutical is paying $400 million to ...

Summit Therapeutics (SMMT) stock gains as Cantor Fitzgerald issues an Overweight rating highlighting the company's lead asset ...

Merck and Bristol-Myers Squibb are key players in cancer treatment. Find out why MRK and BMY stocks have different prospects ...

Merck's stock recently got a cardio boost, jumping 13% in a month thanks to some pulse-quickening developments. The company ...

The deal with startup Dren Bio hands Sanofi a so-called myeloid cell engager that would compete with an array of programs ...

Immutep Limited (ASX: IMM; NASDAQ: IMMP) (“Immutep” or “the Company”), a late-stage immunotherapy company targeting cancer and autoimmune diseases, today announces an upcoming poster presentation for ...

The US Food and Drug Administration (FDA) has granted traditional approval to Merck & Co’s (NYSE: MRK) Keytruda ...